Gossamer Bio in the spotlight (part II)

Despite stock drop, GOSS' seralutinib shows potential as PAH agent, securing $212M for Phase 3 trials

• GOSS traded down 32% on the OLE data release and financing news. We think this reaction focused on the terms of the financing, but overlooked seralutinib’s potential as a PAH-modifying agent. 

• Merck paid $11.5B to acquire Acceleron, which showed it could maintain clinical efficacy through the extension period. Gossamer’s early data demonstrated that clin…